FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary use, not for consumption, not medicines. Research use policy
UK only · Prepared to order · approx. 7 days + Royal Mail Tracked 24 · No international shipping
Britpep
Basket 0
Ipamorelin 5 mg research peptide vial View vial label (BP-IPA-5) →
Peptide · Lyophilised vial

Ipamorelin

Endocrine & receptor-signalling research peptides

Synthetic pentapeptide agonist of the ghrelin receptor (GHS-R1a), used in growth-hormone-secretagogue receptor research.

Areas of research interest
£17.99 ex. VAT · per vial
Available

Prepared to order · approx. 7 days + Royal Mail Tracked 24

SKU BP-IPA-5 · ≥99% (see COA) · Lyophilised powder

For laboratory research use only. Not for human or veterinary use. Not a medicine, food supplement or cosmetic. Purchasers confirm research use, age 18+ and institutional/professional status at checkout. UK delivery only.
Data pending verification. Identity data in the specification below has been compiled for pre-launch and is awaiting verification against supplier documentation and batch COAs. Highlighted fields are unconfirmed.
Note: Salt form (e.g. acetate or TFA) and net peptide content to be confirmed from the supplier COA.

Ipamorelin overview

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue containing the non-proteinogenic residues Aib and D-2-naphthylalanine. It is supplied as a lyophilised solid for in-vitro laboratory research.

Sequence
Aib-His-D-2Nal-D-Phe-Lys-NH₂
Molecular formula
C₃₈H₄₉N₉O₅
Molecular weight
≈711.9 g/mol (free base)
Purity
≥99% (see COA)
Form
Lyophilised powder
Vial sizes & prices
5 mg – £17.99; 10 mg – £37.99 (ex. VAT)
Delivery
UK only · prepared to order (approx. 7 days) then Royal Mail Tracked 24, £5.95

Ipamorelin research background

Clinical trials – mixed results

Evidence status: Findings summarised here include controlled human trials with mixed or negative results, alongside preclinical research. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.

Established research

Peer-reviewed published findings, with references
Overview & discovery history
  • Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) growth-hormone secretagogue. It was described in 1998 by Raun and colleagues as the first selective GH secretagogue [1]. It acts at the receptor later identified as the receptor for ghrelin [2].
Chemical identity
Sequence
Aib-His-D-2Nal-D-Phe-Lys-NH₂
Molecular formula
C₃₈H₄₉N₉O₅
Molecular weight
≈711.9 g/mol (free base)
CAS number
170851-70-4 [TO VERIFY against supplier COA]
Form
Lyophilised powder
Purity
≥99% (see COA)
Format
Lyophilised vial
Vial sizes
5 mg, 10 mg

Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.

Mechanisms investigated
  • GHS-R1a (ghrelin receptor) agonism, causing GH release from the pituitary [1][2].
  • Selectivity: in animal studies, GH release was not accompanied by the ACTH or cortisol increases seen with other secretagogues [1].
  • Pharmacokinetic–pharmacodynamic modelling has been reported in healthy volunteers [3].
Research areas & model types
Research areaModel typeSummary
GH release and selectivityAnimal (pig, rat)[1]
Postoperative ileusRat[5]
PK/PDHuman (healthy volunteers)[3]
Postoperative ileusHuman (Phase 2 RCT)[4]
Human clinical research status
  • A Phase 2 randomised placebo-controlled trial in postoperative ileus after bowel resection found no significant difference from placebo in the primary endpoint [4]. Ipamorelin is not an approved medicine.
Safety observations reported in studies
  • The Phase 2 trial reported that ipamorelin was well tolerated [4].
Known limitations
  • Clinical development for ileus did not show efficacy [4].
Storage & handling for laboratory use

Store at −20 °C. Protect from light.

Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.

  • Allow the sealed vial to reach room temperature before opening to limit condensation.
  • Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
  • Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.

Emerging & theoretical

Unconfirmed — hypotheses & ongoing research

These are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.

Hypotheses proposed by researchers

  • Earlier rodent work led researchers to propose ghrelin-receptor agonists for gastrointestinal motility disorders. The human Phase 2 data did not confirm this [5][4].

Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.

References

  1. Raun K, Hansen BS, Johansen NL et al.. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822 · doi:10.1530/eje.0.1390552
  2. Kojima M, Hosoda H, Date Y et al.. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. PubMed 10604470 · doi:10.1038/45230
  3. Gobburu JV, Agersø H, Jusko WJ et al.. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PubMed 10496658 · doi:10.1023/a:1018955126402
  4. Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. PubMed 25331030 · doi:10.1007/s00384-014-2030-8
  5. Venkova K, Mann W, Nelson R et al.. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009. PubMed 19289567 · doi:10.1124/jpet.108.149211

Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.

Certificates of analysis

[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]

Open the COA checker

Related research compounds

CJC-1295 (without DAC) / Ipamorelin blend research peptide vial
Peptide blend · Lyophilised vial

CJC-1295 (without DAC) / Ipamorelin blend

10 mg
£34.99View
AOD9604 research peptide vial
Peptide · Lyophilised vial

AOD9604

5 mg · 10 mg
From £37.99View
CJC-1295 (with DAC) research peptide vial
Peptide · Lyophilised vial

CJC-1295 (with DAC)

2 mg · 5 mg · 10 mg
From £20.49View
CJC-1295 (without DAC) research peptide vial
Peptide · Lyophilised vial

CJC-1295 (without DAC)

5 mg · 10 mg
From £23.49View

Browse similar compounds: Endocrine & receptor-signalling research peptides or the full catalogue.